United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,111,995.40. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Down 0.6%

Shares of UTHR stock opened at $541.83 on Wednesday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market capitalization of $23.00 billion, a P/E ratio of 20.00, a P/E/G ratio of 1.79 and a beta of 0.57. The firm has a 50-day moving average price of $559.59 and a 200 day moving average price of $526.79.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $6.63 earnings per share. As a group, research analysts expect that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. Bank of America increased their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. HC Wainwright lifted their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

Several large investors have recently made changes to their positions in UTHR. Arjuna Capital boosted its holdings in United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the last quarter. Sage Rhino Capital LLC raised its holdings in United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its holdings in United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. lifted its position in United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its position in United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.